Mutação BRAF em pacientes idosos com carcinoma papilífero

Introducao: A mutacao BRAF representa a alteracao genetica maiscomum do câncer de tireoide e esta foi a descoberta mais notavelneste campo de pesquisa, nos ultimos anos; estao presentes em23-83% dos carcinomas papiliferos e sao altamente especificaspara este tipo histologico. Metodo: Estudamos 22 pacientes,com mais de 65 anos, e diagnostico de carcinoma papiliferosubmetidos a tireoidectomia, analisando a mutacao BRAFV600E atraves de reacao de PCR-RT realizada apos a extracaodo DNA dos blocos de parafina. Resultados: Conseguimosdetectar a ausencia ou presenca da mutacao BRAF V600E em17 pacientes (77,3%). Entre estes 17 carcinomas papiliferos, seteapresentavam a mutacao (41,2%). Demonstramos associacaoestatistica entre a presenca desta mutacao e a variante classicado carcinoma papilifero, alem de tendencia de associacao como extravasamento tireoideano. Discussao: Embora a mutacaoBRAF seja a anormalidade genetica mais comum no carcinomapapilifero, o seu significado prognostico ainda nao esta bemestabelecido. Estudos contraditorios tem sido publicados,provavelmente pela heterogeneidade do carcinoma papilifero aoredor do mundo. Conclusao: a mutacao BRAF, nos pacientesidosos com carcinoma papilifero tem frequencia expressiva, eesta relacionada com sua variante classica.(AU)

[1]  Laura S. Ward,et al.  Analise da expressão do gene BRAF e suas possiveis implicações diagnosticas e prognosticas para pacientes portadores de carcinoma papilifero da tireoide , 2009 .

[2]  M. Ladanyi,et al.  Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. , 2009, Cancer research.

[3]  J. Cerutti,et al.  High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas , 2009, Cancer.

[4]  M. Hirokawa,et al.  BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. , 2009, Endocrine journal.

[5]  J. Cerutti,et al.  Seven-year follow-up of a juvenile female with papillary thyroid carcinoma with poor outcome, BRAF mutation and loss of expression of iodine-metabolizing genes. , 2008, Arquivos brasileiros de endocrinologia e metabologia.

[6]  A. Pinchera,et al.  BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. , 2008, The Journal of clinical endocrinology and metabolism.

[7]  G. Riggins,et al.  Gene Expression Profiling of Papillary Thyroid Carcinoma Identifies Transcripts Correlated with BRAF Mutational Status and Lymph Node Metastasis , 2008, Clinical Cancer Research.

[8]  D. Spandidos,et al.  RKIP and BRAF aberrations in human nasal polyps and the adjacent turbinate mucosae. , 2008, Cancer letters.

[9]  M. Schott.  Selective Growth Inhibition in BRAF Mutant Thyroid Cancer by the Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 , 2008 .

[10]  M. Santoro,et al.  Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. , 2007, The Journal of clinical endocrinology and metabolism.

[11]  Electron Kebebew,et al.  The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer , 2007, Annals of surgery.

[12]  B. Jarzab,et al.  Differentiated thyroid cancer in children and adults: same or distinct disease? , 2007, Hormones.

[13]  E. Puxeddu,et al.  Clinical prognosis in BRAF-mutated PTC. , 2007, Arquivos brasileiros de endocrinologia e metabologia.

[14]  M. Santoro,et al.  New drugs in thyroid cancer. , 2007, Arquivos brasileiros de endocrinologia e metabologia.

[15]  H. Namba,et al.  Clinical implications of pre-operative rapid BRAF analysis for papillary thyroid cancer. , 2007, Endocrine journal.

[16]  H. Namba,et al.  No evidence of ARAF, CRAF and MET mutations in BRAFT1799A negative human papillary thyroid carcinoma. , 2006, Endocrine journal.

[17]  Jung Hun Song,et al.  Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. , 2006, The Journal of clinical endocrinology and metabolism.

[18]  C. Tomlinson,et al.  Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. , 2006, Cancer research.

[19]  A. Pinchera,et al.  Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. , 2006, Endocrine-related cancer.

[20]  R. Marais,et al.  Is BRAF the Achilles' Heel of Thyroid Cancer? , 2006, Clinical Cancer Research.

[21]  J. Fagin,et al.  Inhibitors of Raf Kinase Activity Block Growth of Thyroid Cancer Cells with RET/PTC or BRAF Mutations In vitro and In vivo , 2006, Clinical Cancer Research.

[22]  M. A. García-Cabezas,et al.  The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. , 2006, Endocrine-related cancer.

[23]  T. Fahey.  Type and Prevalence of BRAF Mutations Are Closely Associated With Papillary Thyroid Carcinoma Histotype and Patients' Age But Not With Tumour Aggressiveness , 2006 .

[24]  P. Ladenson,et al.  BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. , 2005, The Journal of clinical endocrinology and metabolism.

[25]  X. Qian,et al.  RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors , 2005, Laboratory Investigation.

[26]  D. Sidransky,et al.  Mutational activation of BRAF is not a major event in sporadic childhood papillary thyroid carcinoma , 2005, Modern Pathology.

[27]  M. Xing,et al.  BRAF mutation in thyroid cancer. , 2005, Endocrine-related cancer.

[28]  Lei Zhang,et al.  Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. , 2005, Cancer research.

[29]  F. Borson‐Chazot,et al.  0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(5):3028–3035 Printed in U.S.A. Copyright © 2005 by The Endocrine Society doi: 10.1210/jc.2004-1394 Silencing of the Tumor Suppressor Gene SLC5A8 Is Associated with BRAF Mutations , 2022 .

[30]  P. Komminoth,et al.  BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors. , 2004, Endocrine-related cancer.

[31]  J. Fagin.  How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. , 2004, The Journal of endocrinology.

[32]  D. Sidransky,et al.  BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment , 2004, Modern Pathology.

[33]  J. Fagin.  Challenging dogma in thyroid cancer molecular genetics--role of RET/PTC and BRAF in tumor initiation. , 2004, The Journal of clinical endocrinology and metabolism.

[34]  M. Santoro,et al.  BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. , 2004, The Journal of clinical endocrinology and metabolism.

[35]  Masahiro Ito,et al.  Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. , 2004, The Journal of clinical endocrinology and metabolism.

[36]  P. Beck‐Peccoz,et al.  BRAF mutations in an Italian cohort of thyroid cancers , 2004, Clinical endocrinology.

[37]  V. Trovisco,et al.  BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas , 2004, Virchows Archiv.

[38]  D. Clark,et al.  Mutational Analysis of BRAF in Fine Needle Aspiration Biopsies of the Thyroid: A Potential Application for the Preoperative Assessment of Thyroid Nodules , 2004, Clinical Cancer Research.

[39]  V. Trovisco,et al.  BRAF mutations are associated with some histological types of papillary thyroid carcinoma , 2004, The Journal of pathology.

[40]  A. Pinchera,et al.  BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. , 2004, The Journal of clinical endocrinology and metabolism.

[41]  M. Nikiforova,et al.  BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. , 2003, The Journal of clinical endocrinology and metabolism.

[42]  H. Namba,et al.  Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. , 2003, The Journal of clinical endocrinology and metabolism.

[43]  Yuri E Nikiforov,et al.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.

[44]  T. Hadar,et al.  Thyroid Carcinoma in Children and Adolescents , 1985, Harefuah.